CWRUObserver.com -Financial News and Headlines - NYSE, Nasdaq, OTC's

[jmhollen]

DNAP - News: (..moving up..) Danger - Convertible Debenture

DNAPrint(TM) genomics, Inc. Secures Up To $8 Million In Financing From La Jolla Cove Investors


SARASOTA, Fla., Dec 03, 2003 /PRNewswire-FirstCall via Comtex/ -- DNAPrint(TM)
genomics, Inc. (OTC Bulletin Board: DNAP) has secured a commitment from La Jolla
Cove Investors, Inc. to invest up to $8 million in the company over
approximately the next two years. The transaction involves a debenture
convertible into common stock and warrants to purchase common stock, resulting
in a commitment of $400,000 per month over a twenty month period. The purchase
price is based on the trading price of the company's stock, and the funding will
begin after the company registers the common stock that the company will issue
in the transaction. DNAPrint(TM) anticipates that the transaction will provide
it with equity to build the business.

"We are extremely excited about the prospects for DNAPrint(TM) now that we have
established a reliable source of capital for the foreseeable future," said
Richard Gabriel, CEO and President of DNAPrint(TM). "This financing, once the
registration process at the SEC is completed, should allow management to build
shareholder value. We expect to be able to increase our revenues by hiring
personnel, expanding operations and aggressively pursuing business opportunities
in the forensics, pharmacogenomics and consumer products arena," said Mr.
Gabriel.

"This investment starts a new phase of development for the company that will
include the expansion of our Clinical Pharmacogenomics Program. DNAPrint(TM) is
now poised to make a significant contribution to the upcoming era of
personalized medicine," said Hector J. Gomez, MD, PhD, and Chairman of the
Company's Board.

Athena Capital Partners, Inc. in Tampa, Florida was the private merchant bank
that brought La Jolla Cove Investors and DNAPrint(TM) together. "This is the
kind of deal that really helps a company like DNAPrint(TM) grow," said Kevin
Cimino, Managing Director and Principal at Athena.

"We are very pleased with the outcome of our arrangement with Athena Capital,
and we look forward to our new relationship with La Jolla Cove. This transaction
recognizes the value of companies like DNAPrint -- companies that are not afraid
to take scientific risks, companies that develop technologies that are neglected
or unforeseen by others and companies that devote their efforts to rapidly
commercializing products for underserved markets," said Tony Frudakis, Founder
and CSO.

Monica Tamborini, CFO and COO of DNAPrint(TM), commented, "We believe
DNAPrint(TM) has a bright future, and this important step will help the
management achieve its objectives. Our goal and our mission are to increase
shareholder value through real growth."

About DNAPrint(TM) genomics, Inc.

DNAPrint genomics, Inc. was founded by a team of scientists with research and
commercial experience in high-level mathematical modeling, programming and
molecular genetics. Two products currently marketed by DNAPrint(TM),
DNAWitness(TM) and the ANCESTRYbyDNA(TM), are a direct result of focused
research by the DNAPrint(TM) research and development team.

In addition to the currently marketed products, DNAPrint(TM) is using
proprietary human genome research methods to develop pharma-predictive tests for
matching patients with drugs based on their genetic constitution, and to
discover disease genes for the development of new drugs. DNAPrint(TM) will
continue to develop new forensic genomics and consumer genomics testing
products. The Company is traded on the Nasdaq OTC Bulletin Board under the
ticker symbol DNAP. For more information about the company, please visit
www.dnaprint.com.

For more information on our genealogical DNA derived test, ANCESTRYbyDNA(TM)
2.0, visit us on line at www.ancestrybydna.com, helping everyone to understand
their genetic heritage.

http://quotes.freerealtime.com/rt/frt/N?symbol=DNAP&art=C2003120300337p0507&SA=Latest%20News